Diabetes Mellitus and Heart Failure

American Journal of Cardiology

Volumn 120, Issue 1, 2017, Pages S37-S47

  Lehrke, Michael ^a   Marx, Nikolaus ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETIC PATIENT; GLYCEMIC CONTROL; HEART FAILURE; HOSPITALIZATION; HUMAN; INCIDENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; PATHOLOGY;

BENZHYDRYL COMPOUNDS; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLUCOSIDES; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; PREVALENCE; PROGNOSIS;

EID: 85020460054     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2017.05.014     Document Type: Article

References (93)

1. 1 Elliott, P., Andersson, B., Arbustini, E., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29 (2008), 270–276.
2. 2 Rubler, S., Dlugash, J., Yuceoglu, Y.Z., Kumral, T., Branwood, A.W., Grishman, A., New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30 (1972), 595–602.
3. 3 Ernande, L., Derumeaux, G., Diabetic cardiomyopathy: myth or reality?. Arch Cardiovasc Dis 105 (2012), 218–225.
4. 4 Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 (2016), 891–975.
5. 5 Thrainsdottir, I.S., Aspelund, T., Hardarson, T., et al. Glucose abnormalities and heart failure predict poor prognosis in the population-based Reykjavik Study. Eur J Cardiovasc Prev Rehabil 12 (2005), 465–471.
6. 6 Thrainsdottir, I.S., Aspelund, T., Thorgeirsson, G., et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 28 (2005), 612–616.
7. 7 Deedwania, P., Patel, K., Fonarow, G.C., et al. Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: findings from a population-based cohort study. Int J Cardiol 168 (2013), 3616–3622.
8. 8 Bahrami, H., Bluemke, D.A., Kronmal, R., et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 51 (2008), 1775–1783.
9. 9 Nichols, G.A., Gullion, C.M., Koro, C.E., Ephross, S.A., Brown, J.B., The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27 (2004), 1879–1884.
10. 10 van Melle, J.P., Bot, M., de Jonge, P., de Boer, R.A., van Veldhuisen, D.J., Whooley, M.A., Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the Heart and Soul Study. Diabetes Care 33 (2010), 2084–2089.
11. 11 Matsue, Y., Suzuki, M., Nakamura, R., et al. Prevalence and prognostic implications of pre-diabetic state in patients with heart failure. Circ J 75 (2011), 2833–2839.
12. 12 Gustafsson, I., Brendorp, B., Seibaek, M., et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 43 (2004), 771–777.
13. 13 Pfeffer, M.A., Braunwald, E., Moyé, L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992), 669–677.
14. 14 Solomon, S.D., St John Sutton, M., Lamas, G.A., et al. Ventricular remodeling does not accompany the development of heart failure in diabetic patients after myocardial infarction. Circulation 106 (2002), 1251–1255.
15. 15 Aguilar, D., Solomon, S.D., Kober, L., et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 110 (2004), 1572–1578.
16. 16 MacDonald, M.R., Petrie, M.C., Varyani, F., et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29 (2008), 1377–1385.
17. 17 Levelt, E., Mahmod, M., Piechnik, S.K., et al. Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes. Diabetes 65 (2016), 44–52.
18. 18 Levelt, E., Pavlides, M., Banerjee, R., et al. Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J Am Coll Cardiol 68 (2016), 53–63.
19. 19 Falcão-Pires, I., Hamdani, N., Borbély, A., et al. Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation 124 (2011), 1151–1159.
20. 20 Wong, T.C., Piehler, K.M., Kang, I.A., et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 35 (2014), 657–664.
21. 21 Shimizu, I., Minamino, T., Toko, H., et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest 120 (2010), 1506–1514.
22. 22 Levelt, E., Rodgers, C.T., Clarke, W.T., et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. Eur Heart J 37 (2016), 3461–3469.
23. 23 Basta, G., Schmidt, A.M., De Caterina, R., Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63 (2004), 582–592.
24. 24 Ramasamy, R., Schmidt, A.M., Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr Heart Fail Rep 9 (2012), 107–116.
25. 25 Benjamin, E.J., Levy, D., Vaziri, S.M., D'Agostino, R.B., Belanger, A.J., Wolf, P.A., Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271 (1994), 840–844.
26. 26 Kadappu, K.K., Boyd, A., Eshoo, S., et al. Changes in left atrial volume in diabetes mellitus: more than diastolic dysfunction?. Eur Heart J Cardiovasc Imaging 13 (2012), 1016–1023.
27. 27 Bonapace, S., Valbusa, F., Bertolini, L., et al. Early impairment in left ventricular longitudinal systolic function is associated with an increased risk of incident atrial fibrillation in patients with type 2 diabetes. J Diabetes Complications 31 (2017), 413–418.
28. 28 Montaigne, D., Marechal, X., Coisne, A., et al. Myocardial contractile dysfunction is associated with impaired mitochondrial function and dynamics in type 2 diabetic but not in obese patients. Circulation 130 (2014), 554–564.
29. 29 Ertunc, M.E., Hotamisligil, G.S., Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res 57 (2016), 2099–2114.
30. 30 Glass, C.K., Olefsky, J.M., Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15 (2012), 635–645.
31. 31 Rijzewijk, L.J., Jonker, J.T., van der Meer, R.W., et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 56 (2010), 225–233.
32. 32 Lowell, B.B., Shulman, G.I., Mitochondrial dysfunction and type 2 diabetes. Science 307 (2005), 384–387.
33. 33 Liesa, M., Shirihai, O.S., Mitochondrial dynamics in the regulation of nutrient utilization and energy expenditure. Cell Metab 17 (2013), 491–506.
34. 34 Fink, B.D., Bai, F., Yu, L., Sivitz, W.I., Impaired utilization of membrane potential by complex II-energized mitochondria of obese, diabetic mice assessed using ADP recycling methodology. Am J Physiol Regul Integr Comp Physiol, 2016, 10.1152/ajpregu.00232.2016 [Epub ahead of print].
35. 35 Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ Res 107 (2010), 1058–1070.
36. 36 Shah, M.S., Brownlee, M., Molecular and cellular mechanisms of cardiovascular disorders in diabetes. Circ Res 118 (2016), 1808–1829.
37. 37 Sverdlov, A.L., Elezaby, A., Qin, F., et al. Mitochondrial reactive oxygen species mediate cardiac structural, functional, and mitochondrial consequences of diet-induced metabolic heart disease. J Am Heart Assoc, 5, 2016, 10.1161/JAHA.115.002555.
38. 38 Neubauer, S., The failing heart–an engine out of fuel. N Engl J Med 356 (2007), 1140–1151.
39. 39 Chokshi, A., Drosatos, K., Cheema, F.H., et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 125 (2012), 2844–2853.
40. 40 Doehner, W., Frenneaux, M., Anker, S.D., Metabolic impairment in heart failure: the myocardial and systemic perspective. J Am Coll Cardiol 64 (2014), 1388–1400.
41. 41 Doehner, W., Rauchhaus, M., Ponikowski, P., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46 (2005), 1019–1026.
42. 42 Bedi, K.C. Jr., Snyder, N.W., Brandimarto, J., et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133 (2016), 706–716.
43. 43 Aubert, G., Martin, O.J., Horton, J.L., et al. The failing heart relies on ketone bodies as a fuel. Circulation 133 (2016), 698–705.
44. 44 Yancy, C., Jessup, M., Bozkurt, B., et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 22 (2016), 659–669.
45. 45 Ahmad, T., Pencina, M.J., Schulte, P.J., et al. Clinical implications of chronic heart failure phenotypes defined by cluster analysis. J Am Coll Cardiol 64 (2014), 1765–1774.
46. 46 Writing Committee Members, Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 134 (2016), e282–e293.
47. 47 Boehringer Ingelheim. Jardiance (empagliflozin) to be studied for the treatment of people with chronic heart failure. Available at: www.boehringer-ingelheim.com/press-release/jardiance-empagliflozin-be-studied-treatment-people-chronic-heart-failure Accessed December 19, 2016.
48. 48 Look AHEAD Research Group, Wing, R.R., Bolin, P., Brancati, F.L., et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369 (2013), 145–154.
49. 49 Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 4 (2016), 913–921.
50. 50 Abed, H.S., Wittert, G.A., Leong, D.P., et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 310 (2013), 2050–2060.
51. 51 Pathak, R.K., Middeldorp, M.E., Meredith, M., et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 65 (2015), 2159–2169.
52. 52 Kirchhof, P., Benussi, S., Kotecha, D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 (2016), 2893–2962.
53. 53 Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ, 343, 2011, d4169.
54. 54 American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care 40 (2017), S64–S74.
55. 55 Aguilar, D., Chan, W., Bozkurt, B., Ramasubbu, K., Deswal, A., Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 4 (2011), 53–58.
56. 56 Evans, J.M., Doney, A.S., AlZadjali, M.A., et al. Effect of metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 106 (2010), 1006–1010.
57. 57 Bristol-Myers Squibb. Glucophage (metformin hydrochloride) prescribing information. January 2009. Available at: http://packageinserts.bms.com/pi/pi_glucophage.pdf Accessed August 8, 2016.
58. 58 US Food and Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. Available at: www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf, April 8, 2016 Accessed May 12, 2016.
59. 59 Crowley, M.J., Diamantidis, C.J., McDuffie, J.R., et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 166 (2017), 191–200.
60. 60 Boussageon, R., Supper, I., Bejan-Angoulvant, T., et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med, 9, 2012, e1001204.
61. 61 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
62. 62 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
63. 63 Ou, S.M., Shih, C.J., Chao, P.W., et al. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 163 (2015), 663–672.
64. 64 Tzoulaki, I., Molokhia, M., Curcin, V., et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ, 339, 2009, b4731.
65. 65 BARI 2D Study Group, Frye, R.L., August, P., Brooks, M.M., et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360 (2009), 2503–2515.
66. 66 Damluji, A.A., Cohen, E.R., Moscucci, M., et al. Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: insights from BARI-2D trial. Int J Cardiol, 2017, 10.1016/j.ijcard.2017.03.048 [Epub ahead of print].
67. 67 Smooke, S., Horwich, T.B., Fonarow, G.C., Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149 (2005), 168–174.
68. 68 ORIGIN Trial Investigators, Gerstein, H.C., Bosch, J., Dagenais, G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367 (2012), 319–328.
69. 69 Gamble, J.M., Chibrikov, E., Twells, L.K., et al. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study. Lancet Diabetes Endocrinol 5 (2017), 43–52.
70. 70 Hernandez, A.V., Usmani, A., Rajamanickam, A., Moheet, A., Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11 (2011), 115–128.
71. 71 US Department of Health and Human Services. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf Accessed November 9, 2016.
72. 72 Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
73. 73 White, W.B., Cannon, C.P., Heller, S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
74. 74 Green, J.B., Bethel, M.A., Armstrong, P.W., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
75. 75 Scirica, B.M., Braunwald, E., Raz, I., et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 130 (2014), 1579–1588.
76. 76 Sato, A., Yoshihisa, A., Kanno, Y., et al. Associations of dipeptidyl peptidase-4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus. ESC Heart Fail 3 (2016), 77–85.
77. 77 Toh, S., Hampp, C., Reichman, M.E., et al. Risk for hospitalized heart failure among new users of saxagliptin, sitagliptin, and other antihyperglycemic drugs: a retrospective cohort study. Ann Intern Med 164 (2016), 705–714.
78. 78 Filion, K.B., Azoulay, L., Platt, R.W., et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 374 (2016), 1145–1154.
79. 79 Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 (2012), 728–742.
80. 80 Pfeffer, M.A., Claggett, B., Diaz, R., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
81. 81 Russell-Jones, D., Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 297 (2009), 137–140.
82. 82 Lau, J., Bloch, P., Schaffer, L., et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 58 (2015), 7370–7380.
83. 83 Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
84. 84 Marso, S.P., Bain, S.C., Consoli, A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
85. 85 Lehrke, M., Marx, N., Cardiovascular effects of incretin-based therapies. Rev Diabet Stud 8 (2011), 382–391.
86. 86 Margulies, K.B., Hernandez, A.F., Redfield, M.M., et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316 (2016), 500–508.
87. 87 Jorsal, A., Kistorp, C., Holmager, P., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19 (2017), 69–77.
88. 88 Lepore, J.J., Olson, E., Demopoulos, L., et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail 4 (2016), 559–566.
89. 89 Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
90. 90 Fitchett, D., Zinman, B., Wanner, C., et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J 37 (2016), 1526–1534.
91. 91 Ferrannini, E., Mark, M., Mayoux, E., CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.
92. 92 Marx, N., McGuire, D.K., Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 37 (2016), 3192–3200.
93. 93 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998), 854–865.